Technology | June 15, 2012

GE Healthcare Introduces Performance SPECT/CT System

Optima NM/CT640 offers CT image quality while keeping dose and ownership costs low

GE Healthcare Introduces Performance SPECT/CT System

June 15, 2012 — At the 2012 Annual Meeting of the Society of Nuclear Medicine (SNM), GE Healthcare introduced the latest addition to its Nuclear Medicine 600 series with a new performance SPECT/CT (single photon emission computed tomography/computed tomography) system, the Optima NM/CT 640. The new system offers nuclear medicine physicians the optimal balance of image quality, patient dose efficiency and low total cost of ownership.

Based on the 600 series’ SPECT technology found in the Discovery NM 630, this system integrates the general-purpose camera with a newly developed 4-slice CT designed for hybrid rather than standalone CT use. The CT, available in 2.5 mm and 5 mm slice thicknesses to optimize dose and resolution required for particular procedures, offers clinicians confidence with routinely low CT dose at 1-2 mSv for a 40-cm abdomen CT scan.

The Optima NM/CT 640 can be fully upgraded on location from a Discovery NM 630 SPECT-only system, and may be upgraded in the future to a 16-slice Discovery NM/CT 670, expanding not only its clinical capability, but offering the potential for research use.

With its small footprint the Optima NM/CT 640 requires minimal renovation and installation costs. With the benefit of optimized CT power, shielding and control room requirements are often eliminated, saving as much as $100,000 compared to higher CT-powered systems.

“At GE Healthcare, we are dedicated to pushing nuclear medicine to its full potential and investing in its future,” said Nathan Hermony, general manager, nuclear medicine, GE Healthcare. “We’re focused on developing equipment that helps customers address the challenges they are confronted with every day: high image quality, low dose and short exam times. Adding the Optima NM/CT 640 to our portfolio helps us strengthen this position, allows customers to upgrade as their needs expand, and continues to benefit clinicians and their patients.”

Adding all the benefits of the Xeleris Workstation with the Evolution technology to the Optima NM/CT 640 reduces the tradeoffs that are often required between acquisition time, dose and image quality by allowing clinicians to feel confident in their diagnosis, reducing time or injected patient dose by up to 50 percent in most scanning procedures while still maintaining excellent image quality. The Xeleris Workstation — which integrates new and existing nuclear medicine equipment, including legacy GE and non-GE devices — is designed to provide consistent results and enhanced workflow. Xeleris can keep clinicians connected to images and applications from picturing archiving and communications systems (PACS) and PCs with their institution and remotely.

For more information: www.gehealthcare.com

Related Content

PET Tracer Identifies Estrogen Receptor Expression Differences in Breast Cancer Patients
News | PET Imaging | August 09, 2018
In metastatic breast cancer, prognosis and treatment is largely influenced by estrogen receptor (ER) expression of the...
Novel PET Imaging Method Could Track and Guide Type 1 Diabetes Therapy
News | PET Imaging | August 03, 2018
Researchers have discovered a new nuclear medicine test that could improve care of patients with type 1 diabetes. The...
Researchers Trace Parkinson’s Damage in the Heart
News | PET Imaging | July 17, 2018
A new way to examine stress and inflammation in the heart will help Parkinson’s researchers test new therapies and...
Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
SNMMI Image of the Year Highlights Theranostic Approach for Advanced Prostate Cancer

IMAGE OF THE YEAR: PSMA PET before and after lutetium-177 PSMA617 theranostics in 8 patients with metastatic prostate cancer who exhausted standard therapeutic options.

68Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177Lu-PSMA617 in 8 patients with PSA decline ≥ 98 percent in a prospective phase II study. Any disease with SUV over 3 is in red. Credit: Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.

News | PET Imaging | June 29, 2018
In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to...
MILabs Introduces Futuristic PET Capabilities on New VECTor6 System
Technology | PET Imaging | June 28, 2018
At the 2018 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, June 23-26, in Philadelphia,...
Philips North America and GE Healthcare Win IMV PET Imaging ServiceTrak Awards
News | PET Imaging | June 25, 2018
IMV, part of the Science and Medicine Group and a market research and business intelligence provider to the imaging...
New ASNC SPECT Imaging Guideline Addresses Advances in Myocardial Perfusion Imaging
News | SPECT Imaging | June 21, 2018
The American Society of Nuclear Cardiology (ASNC) has published an update to its 2010 guidelines for single photon...
FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
Overlay Init